Arthrex Biotech
Arthex Biotech develops RNA-based medicines, specifically antimiR oligonucleotides, to treat diseases with unmet medical needs. Its lead investigational program focuses on Myotonic Dystrophy (DM1) by targeting upregulated miRNA to address the root cause of the disease. The company utilizes a delivery mechanism that conjugates oligonucleotides to fatty acids to improve uptake in muscle tissue at low doses.
Biotechnology
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €1.5M
- Funding rounds
- 1
Investors in Arthrex Biotech
Investors on record for Arthrex Biotech. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Arthrex Biotech?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors